期刊
CANCER SCIENCE
卷 107, 期 9, 页码 1193-1197出版社
WILEY
DOI: 10.1111/cas.12986
关键词
Cancer checkpoints; clinical trial; immunotherapy; lymphocyte-activation gene-3; soluble LAG-3
类别
资金
- IASLC Young Investigator Award
- Pia and Fred R. Hirsch Endowed Chair at the University of Colorado
- Young Program of Shanghai Health Development Planning Commission
Immunotherapy has recently become widely used in lung cancer. Many oncologists are focused on cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1). Immunotherapy targeting the PD-1/PD-L1 checkpoints has shown promising efficacy in non-small cell lung cancer (NSCLC), but questions remain to be answered. Among them is whether the simultaneous inhibition of other checkpoints could improve outcomes. Lymphocyte-activation gene-3 (LAG-3) is another vital checkpoint that may have a synergistic interaction with PD-1/PD-L1. Here we review the LAG-3 function in cancer, clinical trials with agents targeting LAG-3 and the correlation of LAG-3 with other checkpoints.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据